Ethic Inc. Has $1.48 Million Holdings in Hologic, Inc. $HOLX

Ethic Inc. increased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 115.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,977 shares of the medical equipment provider’s stock after purchasing an additional 11,777 shares during the period. Ethic Inc.’s holdings in Hologic were worth $1,483,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. The Manufacturers Life Insurance Company boosted its stake in shares of Hologic by 294.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock worth $718,223,000 after acquiring an additional 8,227,318 shares in the last quarter. Invesco Ltd. lifted its holdings in Hologic by 72.5% in the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after purchasing an additional 3,505,828 shares during the last quarter. Norges Bank bought a new stake in Hologic during the second quarter worth approximately $180,055,000. Allspring Global Investments Holdings LLC grew its holdings in Hologic by 473.5% during the second quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider’s stock valued at $111,180,000 after purchasing an additional 1,405,085 shares during the last quarter. Finally, Black Creek Investment Management Inc. grew its holdings in Hologic by 26.1% during the second quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock valued at $262,453,000 after purchasing an additional 832,444 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Trading Down 0.1%

Hologic stock opened at $74.49 on Friday. The business has a 50 day moving average price of $74.54 and a two-hundred day moving average price of $69.38. The company has a quick ratio of 3.06, a current ratio of 3.75 and a debt-to-equity ratio of 0.50. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $75.34. The stock has a market cap of $16.60 billion, a price-to-earnings ratio of 30.04, a price-to-earnings-growth ratio of 2.11 and a beta of 0.69.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Hologic had a return on equity of 20.13% and a net margin of 13.80%.Hologic’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.01 earnings per share. As a group, equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on HOLX. Argus upped their price objective on shares of Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a report on Friday, September 19th. Wall Street Zen cut shares of Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, October 1st. BNP Paribas Exane downgraded Hologic from an “outperform” rating to a “neutral” rating and set a $79.00 price target on the stock. in a research report on Friday, November 21st. Morgan Stanley boosted their price objective on Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Finally, Evercore ISI set a $78.00 target price on Hologic and gave the company an “outperform” rating in a report on Tuesday, October 7th. Five investment analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. According to data from MarketBeat, Hologic currently has an average rating of “Hold” and an average target price of $79.29.

Insider Transactions at Hologic

In other Hologic news, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the transaction, the director owned 47,336 shares in the company, valued at $3,458,841.52. This trade represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.88% of the stock is owned by company insiders.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.